IGF-1 LR3 is a synthetic 83-amino-acid analog of human insulin-like growth factor 1, engineered so that the binding proteins which normally sequester native IGF-1 grab it only weakly. That single design choice is the whole story: far more of the molecule stays free and active, and its functional half-life stretches from minutes into the range of a full day. The honest bottom line up front is that it remains a research chemical, not an approved medicine, and the material sold online is labeled for laboratory use only.
IGF-1 LR3 is a binding-protein-resistant 83-amino-acid IGF-1 analog with a reported 20 to 30 hour functional half-life that is not FDA-approved and is sold in the United States as a Research Use Only compound.
The name is a build sheet. Native human IGF-1 is a 70-amino-acid single chain folded by three disulfide bonds, while the LR3 form is 83 amino acids because two deliberate edits sit on that backbone. An arginine replaces the glutamic acid at position 3, and a 13-residue extension derived from a methionyl-porcine growth hormone fragment is fused to the amino terminus, and together they cut the analog's affinity for the six IGF binding proteins that otherwise control up to 99 percent of circulating IGF-1.
| Feature | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Length | 70 amino acids | 83 amino acids |
| Position 3 | Glutamic acid | Arginine |
| N-terminus | Native | 13-residue extension |
| Binding-protein affinity | High, up to 99 percent bound | Weak, largely free |
IGF-1 LR3 differs from native IGF-1 by an arginine-for-glutamic-acid substitution at position 3 and a 13-residue N-terminal extension, changes that leave the 83-amino-acid analog only weakly bound by the IGF binding proteins that normally capture up to 99 percent of native IGF-1.
IGF-1 LR3 works through the type 1 IGF receptor, a receptor tyrosine kinase present on nearly every cell. What the LR3 edits change is not the signal but its duration: because the analog escapes the binding proteins, more of it stays free to engage the receptor, and it does so over roughly a day rather than the minutes-to-hours window of unbound native IGF-1.
IGF-1 LR3 activates the type 1 IGF receptor to fire the PI3K/Akt/mTOR anabolic branch and the Ras/Raf/MAPK mitogenic branch, and its binding-protein resistance sustains that signaling for roughly a full day versus minutes to hours for native IGF-1.
The best-documented use of IGF-1 LR3 sits in the laboratory, not the gym. It is a potent, binding-protein-resistant growth-factor supplement in serum-free cell culture, and that validated role is a different category from the experimental self-administration that drives its physique following.
The only validated role of IGF-1 LR3 is as a research reagent in cell culture, animal studies, and bioprocessing, while its use for muscle growth or performance rests on no controlled human clinical trials and is experimental self-administration of an unapproved substance.
The biological rationale is real, and that is exactly what gets overstated. IGF-1 is a central driver of skeletal-muscle growth, but the mechanistic and animal evidence is routinely stretched into human promises the peer-reviewed record does not support.
IGF-1 is genuinely important to muscle biology and IGF-1 LR3 activates that biology in cell culture and animal models, but no peer-reviewed controlled human trial has shown that injected IGF-1 LR3 produces a proven, quantified, safe increase in muscle mass or strength.
IGF-1 LR3 has no approval for human use, and its legal footing depends entirely on the context it sits in. The only IGF-1-based medicine approved in the United States is mecasermin, the native-sequence recombinant form for narrow deficiency indications, which the LR3 analog is not.
IGF-1 LR3 is not an FDA-approved drug and is sold only as a Research Use Only compound, marketing it for human consumption constitutes distributing an unapproved new drug, and it is prohibited at all times in sport under the World Anti-Doping Agency list.
The safety concerns stack, and the most dangerous ones are not the obvious ones. Because IGF-1 shares signaling with insulin, a sustained-action analog can lower blood glucose for hours, and the deeper worry is that chronically driving a proliferation pathway carries real oncologic risk. People with diabetes, active or prior cancer, retinopathy, or who are pregnant face amplified danger, and essentially no controlled human safety data exists for LR3 as used non-clinically.
IGF-1 LR3 carries serious documented hazards including hours-long hypoglycemia that can be fatal untreated and a theoretical oncologic risk from chronically driving IGF-1 proliferation signaling, compounded by unverified research-channel purity and essentially no controlled human safety data.
Within the IGF family the defining axis is duration versus binding-protein resistance, and ranking the compounds on that axis is the useful part. What the ranking cannot do is say which is safe in humans, because none of them carry that evidence.
| Peptide | Duration of action | Distinguishing feature |
|---|---|---|
| Native IGF-1 | Minutes to hours | Heavily bound by IGFBPs |
| IGF-1 DES | Very short | Truncated, extremely potent |
| IGF-1 LR3 | ~1 day | Binding-protein resistant, long free window |
| MGF | Local and brief | Splice variant tied to mechanical loading |
| GH / secretagogues | Indirect | Prompt downstream IGF-1 production, more self-regulated |
IGF-1 LR3 occupies the long-acting, binding-protein-resistant end of the IGF family with a roughly day-long free-circulating window, but that convenience advantage over native IGF-1, IGF-1 DES, MGF, and growth hormone comes with the same unproven-in-humans safety status as its peers.
The dosing that actually appears in the research literature is a cell-culture concentration, and a cell-culture concentration is not a human dose. IGF-1 LR3 has never been developed as a human drug, so no established, evidence-based human dosing regimen exists for it.
In its research setting IGF-1 LR3 is dosed as a cell-culture supplement in the low nanogram-per-milliliter to microgram-per-milliliter range, a controlled in-vitro measurement, and no established evidence-based human dosing regimen exists because it has never been developed as a human drug.
As a peptide, IGF-1 LR3 is fragile, and laboratory handling follows well-understood conservation practices. The reason it matters beyond bench housekeeping is that outside a controlled lab these safeguards are routinely skipped, adding infection and unknown-breakdown-product risk to any injected solution.
In proper laboratory handling IGF-1 LR3 is reconstituted gently in a sterile diluent, the lyophilized powder is kept frozen and dark while the reconstituted solution is held cold and shielded from freeze-thaw cycles, and aseptic technique is standard because the growth-promoting solution readily supports contamination.
Verifying an IGF-1 LR3 product comes down to how its identity, purity, and actual content were measured, and by whom. Independent third-party testing carries far more weight than a vendor's own assurances, and even a genuine certificate cannot lift a research chemical to pharmaceutical-grade safety.
An IGF-1 LR3 product's identity is confirmed by mass spectrometry and its purity by HPLC documented in a batch-specific third-party certificate of analysis, but because research-channel material is not made under pharmaceutical good-manufacturing-practice controls, no certificate can validate it as safe for human use.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 LR3. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
